Literature DB >> 8458386

Interleukin 6 is not required for antigen-specific antibody responses by human B cells.

K E Costelloe1, S H Smith, R E Callard.   

Abstract

Interleukin-6 (IL-6) is a late-acting differentiation factor for human B cells activated by polyclonal mitogens such as pokeweed mitogen (PWM) and Staphylococcus aureus Cowan strain I, but its role in specific antibody responses has not been established. We show here that IL-6 has no consistent effect on specific antibody responses by tonsillar mononuclear cells (TMC) stimulated with influenza virus. A blocking IL-6 antibody also had no effect on antibody production, suggesting that endogenous IL-6 production was not required. In control experiments, this antibody inhibited PWM-stimulated immunoglobulin secretion and proliferation of the IL-6-dependent B cell line B9. A requirement for IL-6 in responses of unfractionated TMC may have been disguised by the presence of T cells. To overcome this problem, we investigated the effect of IL-6 on specific antibody production by T-depleted B cells stimulated with antigen in the presence of IL-2, which is a T cell replacing factor (TRF) for human B cells. Specific antibody production was restored by IL-2, but not IL-6. Neither IL-6 nor anti-IL-6 antibody had any consistent effect on specific antibody production by purified B cells stimulated with antigen and TRF. These experiments show that IL-6 does not have a significant role in antigen (influenza virus)-specific antibody responses by human B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458386     DOI: 10.1002/eji.1830230436

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

Review 1.  Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses.

Authors:  C E Taylor
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

2.  Protective immunity to rotavirus shedding in the absence of interleukin-6: Th1 cells and immunoglobulin A develop normally.

Authors:  J L VanCott; M A Franco; H B Greenberg; S Sabbaj; B Tang; R Murray; J R McGhee
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis.

Authors:  Shunsuke Mori; Yukitaka Ueki; Naoyuki Hirakata; Motohiro Oribe; Toshihiko Hidaka; Kazunori Oishi
Journal:  Ann Rheum Dis       Date:  2012-08-11       Impact factor: 19.103

4.  Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.

Authors:  Meliha Crnkic Kapetanovic; Tore Saxne; Göran Jönsson; Lennart Truedsson; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2013-10-30       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.